148 related articles for article (PubMed ID: 33796411)
1. Crystal structure of human interleukin-2 in complex with TCB2, a new antibody-drug candidate with antitumor activity.
Kim J; Lee JY; Park SY; Lee YJ; Kim MS
Oncoimmunology; 2021 Mar; 10(1):1899671. PubMed ID: 33796411
[TBL] [Abstract][Full Text] [Related]
2. TCB2, a new anti-human interleukin-2 antibody, facilitates heterodimeric IL-2 receptor signaling and improves anti-tumor immunity.
Lee JY; Lee E; Hong SW; Kim D; Eunju O; Sprent J; Im SH; Lee YJ; Surh CD
Oncoimmunology; 2020; 9(1):1681869. PubMed ID: 32002288
[TBL] [Abstract][Full Text] [Related]
3. rhIL-7-hyFc and hIL-2/TCB2c combination promotes an immune-stimulatory tumor microenvironment that improves antitumor efficacy of checkpoint inhibitors.
Lee M; Im SK; Baek S; Ji M; Kim M; Lee EJ; Ji ST; Ferrando-Martinez S; Wolfarth A; Lee JY; Kim D; Choi D
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38471713
[TBL] [Abstract][Full Text] [Related]
4. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
[TBL] [Abstract][Full Text] [Related]
5. An IL-2-grafted antibody immunotherapy with potent efficacy against metastatic cancer.
Sahin D; Arenas-Ramirez N; Rath M; Karakus U; Hümbelin M; van Gogh M; Borsig L; Boyman O
Nat Commun; 2020 Dec; 11(1):6440. PubMed ID: 33353953
[TBL] [Abstract][Full Text] [Related]
6. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
Lopes JE; Fisher JL; Flick HL; Wang C; Sun L; Ernstoff MS; Alvarez JC; Losey HC
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293
[TBL] [Abstract][Full Text] [Related]
7. TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer.
Rosen DB; Kvarnhammar AM; Laufer B; Knappe T; Karlsson JJ; Hong E; Lee YC; Thakar D; Zúñiga LA; Bang K; Sabharwal SS; Uppal K; Olling JD; Kjaergaard K; Kurpiers T; Schnabel M; Reich D; Glock P; Zettler J; Krusch M; Bernhard A; Heinig S; Konjik V; Wegge T; Hehn Y; Killian S; Viet L; Runz J; Faltinger F; Tabrizi M; Abel KL; Breinholt VM; Singel SM; Sprogøe K; Punnonen J
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35817480
[TBL] [Abstract][Full Text] [Related]
8. Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2.
Arenas-Ramirez N; Zou C; Popp S; Zingg D; Brannetti B; Wirth E; Calzascia T; Kovarik J; Sommer L; Zenke G; Woytschak J; Regnier CH; Katopodis A; Boyman O
Sci Transl Med; 2016 Nov; 8(367):367ra166. PubMed ID: 27903862
[TBL] [Abstract][Full Text] [Related]
9. IL-15 induces the release of soluble IL-2Ralpha from human peripheral blood mononuclear cells.
Treiber-Held S; Stewart DM; Kurman CC; Nelson DL
Clin Immunol Immunopathol; 1996 Apr; 79(1):71-8. PubMed ID: 8612353
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and antitumor activity of a mutant type of interleukin 2.
Dehghan R; Beig Parikhani A; Zeinali S; Shokrgozar M; Amanzadeh A; Ajdary S; Ahangari Cohan R; Talebkhan Y; Behdani M
Sci Rep; 2022 Mar; 12(1):5376. PubMed ID: 35354847
[TBL] [Abstract][Full Text] [Related]
11. Antibodies to Interleukin-2 Elicit Selective T Cell Subset Potentiation through Distinct Conformational Mechanisms.
Spangler JB; Tomala J; Luca VC; Jude KM; Dong S; Ring AM; Votavova P; Pepper M; Kovar M; Garcia KC
Immunity; 2015 May; 42(5):815-25. PubMed ID: 25992858
[TBL] [Abstract][Full Text] [Related]
12. Effect of anti-IL-2Ralpha antibody on IL-2-induced Jak/STAT signaling.
Tkaczuk J; Yu CL; Baksh S; Milford EL; Carpenter CB; Burakoff SJ; McKay DB
Am J Transplant; 2002 Jan; 2(1):31-40. PubMed ID: 12095053
[TBL] [Abstract][Full Text] [Related]
13. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells.
Krieg C; Létourneau S; Pantaleo G; Boyman O
Proc Natl Acad Sci U S A; 2010 Jun; 107(26):11906-11. PubMed ID: 20547866
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibodies against the human interleukin-11 receptor alpha-chain (IL-11Ralpha) and their use in studies of human mononuclear cells.
Blanc C; Vusio P; Schleinkofer K; Boisteau O; Pflanz S; Minvielle S; Grötzinger J; Müller-Newen G; Heinrich PC; Jacques Y; Montero-Julian FA
J Immunol Methods; 2000 Jul; 241(1-2):43-59. PubMed ID: 10915848
[TBL] [Abstract][Full Text] [Related]
15. Direct inhibition of interleukin-2 receptor alpha-mediated signaling pathway induces G1 arrest and apoptosis in human head-and-neck cancer cells.
Kuhn DJ; Dou QP
J Cell Biochem; 2005 May; 95(2):379-90. PubMed ID: 15779002
[TBL] [Abstract][Full Text] [Related]
16. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
Swiatecka-Urban A
Paediatr Drugs; 2003; 5(10):699-716. PubMed ID: 14510627
[TBL] [Abstract][Full Text] [Related]
17. The soluble IL-2 receptor α/CD25 as a modulator of IL-2 function.
Lokau J; Petasch LM; Garbers C
Immunology; 2024 Mar; 171(3):377-387. PubMed ID: 38037265
[TBL] [Abstract][Full Text] [Related]
18. Surface and intracellular interleukin-2 receptor expression on various resting and activated populations involved in cell-mediated immunity in human peripheral blood.
Hodge S; Hodge G; Flower R; Han P
Scand J Immunol; 2000 Jan; 51(1):67-72. PubMed ID: 10632978
[TBL] [Abstract][Full Text] [Related]
19. Structural basis of immunosuppression by the therapeutic antibody daclizumab.
Yang H; Wang J; Du J; Zhong C; Zhang D; Guo H; Guo Y; Ding J
Cell Res; 2010 Dec; 20(12):1361-71. PubMed ID: 20820193
[TBL] [Abstract][Full Text] [Related]
20. Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection.
VanDyke D; Iglesias M; Tomala J; Young A; Smith J; Perry JA; Gebara E; Cross AR; Cheung LS; Dykema AG; Orcutt-Jahns BT; Henclová T; Golias J; Balolong J; Tomasovic LM; Funda D; Meyer AS; Pardoll DM; Hester J; Issa F; Hunter CA; Anderson MS; Bluestone JA; Raimondi G; Spangler JB
Cell Rep; 2022 Oct; 41(3):111478. PubMed ID: 36261022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
